In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents

Oral Microbiology and Immunology

Volumn 15, Issue 4, 2000, Pages 245-248

  Waltimo, Tuomas M T ^a,b   Orstavik D ^a   Meurman, J H ^c   Samaranayake, L P ^c   Haapasalo, M P P ^c  

^a Nordisk Institutt for Odontologiske Materialer   (Norway)

^b Institute of Dentistry   (Finland)

^c NONE

Author keywords

5 fluorocytosine; Amphotericin B; Antifungal susceptibility; Candida albicans; Clotrimazole; Fluconazole; Miconazole

Indexed keywords

EID: 0033939867     PISSN: 09020055     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-302x.2000.150406.x     Document Type: Article

References (25)

1. Berardinelli S, Opheim DJ. New germ tube medium for the identificaton of Candida albicans. J Clin Microbiol 1985: 22: 861-862.
2. Ellepola ANB, Samaranayake LP. Oral candidal infections and antimycotics. Rev Oral Biol Med (in press).
3. Haapasalo HK, Sirén EK, Waltimo TMT, Ørstavik D, Haapasalo MPP. Inactivation of local root canal medicaments by dentin. Int Endod J (in press).
4. Hunter KD, Gibson J, Lockhart P, Pithie A, Bagg J. Fluconazole resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998: 85: 558-564.
5. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997: 25: 843-846.
6. McGinnis MR, Rinaldi MG. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In: Lorian V, ed. Antibiotics in laboratory medicine. 2nd edn. New York: Academic Press, 1985: 223-281.
7. Medoff G, Brajtburg J, Kobayashi GS. Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol 1983: 23: 303-330.
8. Monteil RA, Madinier I, Le Fichoux Y. In vitro antifungal resistance of oral Candida albicans strains in non-AIDS patients. Oral Microbiol Immunol 1997: 12: 126-128.
9. Nair PNR, Sjögren U, Krey G, Kahnberg K-E, Sundqvist G. Intraradicular bacteria and fungi in root-filled, asymptomatic human teeth with therapy-resistant periapical lesions: a long-term light and electron microscopic follow-up study. J Endod 1990: 16: 580-588.
10. Rams TE, Babalola OO, Slots J. Subgingival occurrence of enteric rods, yeasts and staphylococci after systemic doxycycline therapy. Oral Microbiol Immunol 1990: 5: 166-168.
11. Rex JH, Phaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum NA et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997: 24: 235-247.
12. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998: 42: 129-134.
13. Sen BH, Piskin B, Demirci D. Observation of bacteria and fungi in infected root canals and dentinal tubules by SEM. Endod Dent Traumatol 1995: 11: 6-9.
14. Sen BH, Safavi KE, Spångberg LS. Colonization of Candida albicans on cleaned human dental hard tissues. Arch Oral Biol 1997: 42: 513-520.
15. Sen BH, Safavi KE, Spångberg LS. Growth patterns of Candida albicans in relation to radicular dentin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997: 84: 68-73.
16. Slots J, Rams TE, Listgarten MA. Yeasts, enteric rods and pseudomonas in the subgingival flora of severe adult periodontitis. Oral Microbiol Immunol 1988: 3: 47-52.
17. Surarit R, Shepherd MG. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet Mycol 1987: 25: 403-113.
18. Vanden Bossche H, Warnouck DW, Dupont B, Kerridge D, Sen Gupta S, Improvisi L et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994: 32: 189-202.
19. Vazquez JA, Arganoza MT, Boikov D, Yoon S, Sobel JD, Akins RA. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to inhibitory levels of azoles. J Clin Microbiol 1998: 36: 2690-2695.
20. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 1983: 32: 79-85.
21. Waltimo TMT, Sirén EK, Torkko HLK, Olsen I, Haapasalo MPP. Fungi in therapy-resistant apical periodontitis. Int Endod J 1997: 30: 96-101.
22. Waltimo TMT, Sirén EK, Ørstavik D, Haapasalo MPP. Susceptibility of oral Candida species to calcium hydroxide in vitro. Int Endod J 1999: 32: 94-98.
23. Waltimo TMT, Ørstavik D, Sirén EK, Haapasalo MPP. In vitro susceptiblity of Candida albicans to four disinfectants and their combinations. Int Endod J 1999: 32: 421-429.
24. Waltimo TMT, Ørstavik D, Sirén EK, Haapasalo MPP. In vitro yeast infection of human dentin. J Endod (in press).
25. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998: 11: 382-402.